About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Effect of FAn-7 in UC Activity | Clinical Trials | Clareo Health

Back to clinical trial search

UNKNOWNEARLY Phase 1NCT01771224

Effect of FAn-7 in UC Activity

Introduction: Inflammatory bowel disease (IBD) refers to two chronic diseases that cause intestinal inflammation, ulcerative colitis (UC) and Crohn's disease (CD). The conventional treatment is not ef...

Lead sponsor: National Institute of Medical Sciences and Nutrition, Salvador Zubiran•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Contacts

Jesus K Yamamoto, MD, PhD

CONTACT

54870900 kazuofurusho@hotmail.com

Nallely Bueno, MSc

CONTACT

54870900 nallely_bh5@yahoo.com.mx

Sponsors

Lead Sponsor

National Institute of Medical Sciences and Nutrition, Salvador Zubiran

Age

18 - 59 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Patients with a histopathologically confirmed diagnosis of UC.
•With mild and moderate disease.
•Patients treated with only doses of 5-aminosalicylates (5-ASA)
•BMI, 18 to 34.9 kg/m2
•Born in Mexico the last two generations
•Each patient will be asked to sign and date the consent form, to indicate that you agree to participate.

Exclusion Criteria

•Patient with associated diseases such as diabetes mellitus, hypertension, dyslipidemia, atherosclerosis and malabsorption syndrome.
•With autoimmune diseases (lupus, HIV, cancer and hepatitis), colitis (infectious, post-radiation, post-drug, indeterminate) and Crohn's Disease.
•If the patient use drugs that inhibit fat absorption.
•Patients after partial or total resection of stomach or small intestine.
•Steroid users.
•Patients in remission histology, clinical and endoscopic.
•Patients treated with FAn-3,6 or 9.

Related studies

RECRUITINGPhase 4

Upadacitinib Versus Infliximab as Second-Line Treatment for Acute Severe Ulcerative Colitis（UPRISE）

NCT07550673 · Acute Severe Ulcerative Colitis

Association Between LRG and Histologic Remission in Ulcerative Colitis

NCT06372613 · Ulcerative Colitis in Histologic Remission

RECRUITINGPhase 1/2

A Study of MB-001 in Moderately to Severely Active Ulcerative Colitis

NCT07374471 · Ulcerative Colitis (UC)

Exploring Fecal Calprotectin Levels, Maternal and Infant Microbiota, Infant Health, Nutrition, and Adverse Pregnancy Outcomes With Patient With Inflammatory Bowel Disease

NCT07385807 · IBD (Inflammatory Bowel Disease), IBD, and more

RECRUITINGPhase 2

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

NCT06226883 · Inflammatory Bowel Diseases, Crohn's Disease

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: January 18, 2013Terms

Trial snapshot

StatusUNKNOWN

PhaseEARLY_PHASE1

Enrollment20

Start dateJan 2013

Last updatedJan 18, 2013

Condition

Inflammatory Bowel Disease Ulcerative Colitis

Locations shown

INCMNSZ

DF, Tlalpan

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 18, 2013Data synced to Clareo: May 3, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions